 |
 Video: What is a Stock Split?
|
|
|
| ArQule is a biopharmaceutical company engaged in the research and development of therapeutics to treat cancers and rare diseases. Co.'s clinical pipeline includes: ARQ 531, which is a reversible dual inhibitor of both wild type and C481S-mutant Bruton's tyrosine kinase for B-cell malignancies refractory to other therapeutic options; Miransertib, which is a selective inhibitor of protein kinase B (AKT) in combination with the hormonal therapy, anastrozole; ARQ 751, which is a selective inhibitor of AKT for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase and tensin homolog (PTEN) mutations or that are PTEN null; and Derazantinib, which is a multi-kinase inhibitor. According to our ARQL stock split history records, ARQL has had 0 splits. | |
|
ARQL (ARQL) has 0 splits in our ARQL stock split history database.
Looking at the ARQL stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into ARQL shares, starting with a $10,000 purchase of ARQL, presented on a split-history-adjusted basis factoring in the complete ARQL stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/22/2014 |
|
| End date: |
01/16/2020 |
|
| Start price/share: |
$1.75 |
|
| End price/share: |
$20.00 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
1,042.86% |
|
| Average Annual Total Return: |
52.87% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$114,277.12 |
|
| Years: |
5.74 |
|
|
|
|
|
